Dossier assessment

Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-155
Last updated

Report documents

  1. Extract of dossier assessment

    Cemiplimab (cutaneous squamous cell carcinoma, CSCC) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-155_en
  2. Dossier assessment

    Cemiplimab (cutaneous squamous cell carcinoma, CSCC) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-155

Drug assessment at a glance

  1. Drug assessment at a glance

    Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 203 kB, EN, not accessible

Dossier assessment

Indication:

Adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation; adjuvant treatment

Result of dossier assessment:

Added benefit not proven

Press releases

Cemiplimab for cutaneous squamous cell carcinoma: no suitable data due to the short duration of follow-up

To rule out a recurrence, patients must be followed up for a sufficiently long period – even after the end of treatment. This is not always the case in the manufacturers’ studies. This is also illustrated by the example of cemiplimab in cutaneous squamous cell carcinoma.

Additional information

Federal Joint Committee (G-BA)

05-06-2026 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A25-155
Commission
Commission awarded on 15.12.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-155_en

Connected Projects

  1. Dossier assessment

    Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-36
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-37
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-97
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-98
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Cemiplimab - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-60
    Last updated

    Status: Commission completed

  6. Addendum

    Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Addendum to Project A25-155

    Project no.
    A26-44
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form